Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.
Oliko sinulla jo tili?
Follow this company like 3693 other investors.
Faron announced earlier today that the company’s New Drug (IND) application to initiate the phase I/II BEXMAB study with lead candidate Bexmarilimab has been approved by both the US Food and Drug Administration (FDA) and the Finnish Medicines Agency
Faron Pharmaceuticals Ltd.
("Faron" or "Company")
Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate
Ex Vivo Data Presented at EHA2022 Congress Suggest Critical Role for Clever-1 in
Molecular Cancer Therapeutics Publishes Research on the Nonclinical Characterization of Bexmarilimab
Press release, May 9, 2022 at 02:00 AM (EDT) / 07:00 AM (BST) / 09:00 AM (EEST)
Faron Pharmaceuticals Ltd
("Faron" or the "Company")
Grant of options
Company announcement, 04 May 2022 at 1:15 PM (EEST) 11:15 AM (BST) / 6:15 AM (EDT)
Board Changes
Company announcement, April 22, 2022 at 15:01 PM (EEST) / 13:01 PM (BST) / 8:01 AM (EDT)
Faron Pharmaceuticals Ltd ("Faron" or the "Company")
Results of the Annual General Meeting and Decisions of the Board of Directors
Company announcement, April 22, 2022 at 15:00 PM (EEST) / 13:00 PM (BST) / 8:00 AM (EDT)
TURKU, FINLAND- The annual general meeting ("AGM") of Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) took place at Event Venue Eliel inHelsinki, Finlandtoday, 22 April 2022.
Faronin toimitusjohtajan Markku Jalkasen katsaus vuoden 2022 yhtiökokouksessa.
Redeye initiates coverage of Faron Pharmaceuticals, a Finnish biotech company focused on developing next-generation immunotherapy, its three promising pipeline projects provides multiple inflection points ahead.
